GENERATING INNOVATION IN OPHTHALMIC DRUG DISCOVERY
Pharmacology & Toxicology Consulting Services in Ophthalmology
GENERATING INNOVATION IN OPHTHALMIC DRUG DISCOVERY
Pharmacology & Toxicology Consulting Services in Ophthalmology
About Us
Simon Kaja, PhD
Andrew Payne, PhD
Andrew Payne, PhD
Dr. Kaja is an experienced neuropharmacologist and with more than fifteen years' experience in the academic, biotech and pharmaceutical industry setting as an expert in ocular drug discovery and development.
Dr. Kaja is Chief Scientific Officer and Vice President for Experimentica Ltd., a preclinical CRO specializing in ophthalmic model
Dr. Kaja is an experienced neuropharmacologist and with more than fifteen years' experience in the academic, biotech and pharmaceutical industry setting as an expert in ocular drug discovery and development.
Dr. Kaja is Chief Scientific Officer and Vice President for Experimentica Ltd., a preclinical CRO specializing in ophthalmic models. In addition, Dr. Kaja holds an academic appointment at Loyola University Chicago, where he serves as the Dr. John P. and Therese E. Mulcahy Endowed Professor of Ophthalmology and Director of the Visual Neurobiology and Signal Transduction Laboratory and oversees and NIH-funded research program in ophthalmic drug discovery.
Dr. Kaja brings hands-on and managerial experience to K&P Scientific LLC. Dr. Kaja consults on all aspects of ocular drug discovery and development.
Andrew Payne, PhD
Andrew Payne, PhD
Andrew Payne, PhD
Dr. Payne has completed his trainig in pharmacology and neuroscience and brings a strong background of entrepreneurship to K&P Scientific LLC.
Dr. Payne's research interest lies in drug discovery for neurodegenerative diseases, particularly Alzheimer's disease and neurodegenerative diseases of the visual system, focusing on evolutionary
Dr. Payne has completed his trainig in pharmacology and neuroscience and brings a strong background of entrepreneurship to K&P Scientific LLC.
Dr. Payne's research interest lies in drug discovery for neurodegenerative diseases, particularly Alzheimer's disease and neurodegenerative diseases of the visual system, focusing on evolutionary conserved signaling pathways as novel targets.
With a vision for novel, innovative products for research, Dr. Payne heads the New Products division at K&P Scientific LLC and serves as President of the company.